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1. Need for digital health during the COVID-19 pandemic 
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), started in the city of Wuhan late in 2019. Within a few months, the disease spread toward 
all parts of the world and was declared a pandemic on March 11, 2020. The current health care dilemma 
worldwide is how to sustain the capacity for quality services not only for those suffering from COVID-19 
but also for non-COVID-19 patients, all while protecting physicians, nurses, and other allied health care 
workers.  
The pandemic poses challenges to electrophysiologists at several levels. Hospitalized COVID-19-positive 
patients may have preexisting arrhythmias, develop new arrhythmias, or be placed at increased 
arrhythmic risk from therapies for COVID-19. Cardiac arrhythmia incidence in hospitalized patients has 
been documented in a few published studies, with reported rates of 7.9%1 and 16.7%2 in hospitals in New 
York City and Wuhan, respectively, and up to 44%2 in patients requiring intensive care. Life-threatening 
arrhythmias (ventricular tachycardia [VT]/ventricular fibrillation [VF]) can occur in up to 6% of hospitalized 
patients with COVID-19 infection.3 There have also been several case reports of atrioventricular block in 
hospitalized patients, which is otherwise rarely described during viral illness.4,5 Although the residual left 
ventricular dysfunction and arrhythmic risk are currently unknown, preliminary pathophysiological,6 
histological,7 and imaging8 data suggest that SARS-CoV-2 infection holds the potential to induce durable 
myocardial changes predisposing to arrhythmias or heart failure. 
Electrocardiographic monitoring and inpatient monitoring services may become necessary but face the 
potential hurdles of limited telemetry wards, contamination of equipment and infection of health care 
personnel, and shortage of personal protective equipment.9,10 In parallel, there is a continued 
responsibility to maintain care of COVID-19-negative patients with arrhythmias. These pressures have led 
to inventive utilization and adaptation of existing telemedicine technologies as alternative options. 
This document discusses how digital health may facilitate electrophysiology practice for patients with 
arrhythmia, whether hospitalized for COVID-19 or not. The representation of authors from some of the 
most severely affected countries, such as China, Spain, Italy, and the United States, is a tribute from our 
worldwide community to those colleagues who have worked on the front lines of the pandemic.  
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2.  Monitoring strategies during a pandemic: Here to stay 
In light of the current pandemic, monitoring strategies should focus on selecting high-risk patients in need 
of close surveillance and using alternative remote recording devices to preserve personal protective 
equipment and protect health care workers from potential contagious harm. 
Inpatient 
For inpatient monitoring, telemetry is reasonable when there is concern for clinical deterioration (as may 
be indicated by acute illness, vital signs, or sinus tachycardia), or in patients with cardiovascular risk factors 
and/or receiving essential QT-prolonging medications. Telemetry is generally not necessary for persons 
under investigation without concern for arrhythmias or clinical deterioration and in those not receiving 
QT-prolonging drug therapy. In situations in which a hospital’s existing telemetry capacity has been 
exceeded by patient numbers or when conventional telemetry monitoring is not feasible, such as off-site or 
nontraditional hospital units, mobile devices may be used, for example, mobile cardiac outpatient telemetry 
(MCT) as an adjunctive approach to support inpatient care.11-15 The majority of MCT devices can provide 
continuous arrhythmia monitoring using a single-lead electrocardiogram (ECG) and allow for real-time and 
offline analysis of long-term ECG data. Telemetry can be extended using patch monitoring.16,17 
Smartphone ECG monitors are wireless and have also been utilized during the current pandemic. 
Information is limited, however, on how parameters such as QTc measured on a single- (or limited 
number) lead ECG can reliably substitute for 12-lead ECG information.18,19 In one study, QT was 
underestimated by smartphone single-lead ECG.20 
Outpatient  
The principles of remote patient management, crossing geographic, social, and cultural barriers, can be 
extended to outpatient care and are important to maintain continuity of care for non-COVID-19 
patients.21-23 Virtual clinics move far beyond simple telephone contacts by integrating information from 
photos, video, mobile heart rhythm and mobile health devices recording ECG, and remote cardiovascular 
implantable electronic device (CIED) interrogations.24 A variety of platforms have been developed and 
used specifically to provide telehealth to patients via video teleconferencing25,26 (Table 1). Most health 
care centers have expanded use of telemedicine, with some reporting 100% transformation of in-person 
clinic visits to telemedicine-based visits in order to maintain care for non-COVID-19 patients, thus 
obviating their need to come to the hospital or clinic. This supplements social distancing measures and 
reduces the risk of transmission, especially for the older and more vulnerable populations. It also becomes 
a measure to control intake into emergency rooms and outpatient facilities and to permit rapid access 
when necessary to subspecialists. 
Electrophysiology is well placed for virtual consultations. All preobtained data, including ECGs, ambulatory 
ECG monitoring, cardiac imaging, and coronary angiography can be adequately reviewed electronically. 
Digital tools such as direct-to-consumer mobile ECG (Table 2) and wireless blood pressure devices can be 
used to further complement the telehealth visit without in-person contact. CIED, wearable/mobile health, 
and clinical data can be integrated into clinician workflow.  
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Table 1  Examples of commonly used platforms for telehealth25-27 
 Platform  Website 
HIPAA- or PHI-secure 
telehealth platform 
accuRx* https://www.accurx.com 
AMD Global Telemedicine† https://www.amdtelemedicine.com/telemedicine-products/Working-Clinic-Telemedicine.html 
American Well‡ https://business.amwell.com/solution-overview 
Attend Anywhere* https://www.attendanywhere.com 
BlueJeans for Healthcare‡ https://www.bluejeans.com/use-cases/healthcare 
Care Connect by KRY/LIVI§ https://www.kry.care 
Caregility‡ https://caregility.com/uhe-applications 
Cisco Webex† https://www.webex.com/webexremotehealth.html 
ClickDoc§ https://www.cgm.com/be/index.fr.jsp 
Conexa Saúde¶  https://www.conexasaude.com.br 
Docobo* https://www.docobo.co.uk 
Doctena§ https://secure.doctena.com 
Doctorlink*  https://www.doctorlink.com/video-consultation 
Doximity‡  https://www.doximity.com 
Doxy.me‡ https://doxy.me 
EMIS Health Video Consult* https://www.emishealth.com/products/video-consultation 
Exprivia§ https://www.exprivia.it 
FaceTalk§ https://facetalk.nl 
Google G Suite†  https://gsuite.google.com/industries/healthcare 
Helena§ https://qa.helena.care 
Intersysto§ http://www.intersysto.eu 
InTouch Health‡ https://intouchhealth.com/telehealth-solutions 
pMD‡  https://www.pmd.com/secure-messaging-telemedicine 
Microsoft Teams/Skype for Business E3 
and E5†  
https://www.microsoft.com/en-us/microsoft-
365/microsoft-teams/healthcare-solutions 
Signal§,Δ https://signal.org 
Silicon Practice FootFall*  https://www.siliconpractice.co.uk/video-consultations 
Spruce‡ https://www.sprucehealth.com 
TeleMedi§ https://telemedi.be 
Updox‡ https://www.updox.com 
US Department of Veterans Affairs Video 
Connect‡  https://www.mobile.va.gov/app/va-video-connect 
VSee‡  https://vsee.com 
Zoom for Healthcare† https://zoom.us/healthcare 
Proprietary EMR telehealth platforms      
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Video-conferencing 
platforms (not HIPAA- 
or PHI-secure) 
GoToMeeting  
Skype  
Zoom   
Non-public-facing 
mobile 
communication 
platforms (not HIPAA- 
or PHI-secure) 
Apple FaceTime   
Google Duo   
Google Hangouts   
WhatsApp   
*United Kingdom. †Global. ‡United States. §Europe. ¶South America—Brazil. ∆Encrypted, but not specifically a telehealth 
platform. EMR = electronic medical record; HIPAA = Health Insurance Portability and Accountability Act; PHI = protected health 
information. 
  
Table 2    Examples of remote ECG and heart rate monitoring devices  
  Device Type CE mark FDA clearance 
Additional 
features/Notes Website 
Handheld 
devices 
AliveCor 
KardiaMobile  Wireless Yes Yes 
FDA cleared for 
AF (1-lead) and 
for QTc (6L) for 
COVID-19 
patients on 
HCQ±AZM 
https://www.alivecor.com/ka
rdiamobile  
Beurer ME 90 Wireless 1-lead ECG Yes No   
https://www.beurer.com/we
b/gb/products/medical/ecg-
and-pulse-oximeter/mobile-
ecg-device/me-90-
bluetooth.php  
Cardiac Designs 
ECG Check 
Wireless 
1-lead ECG  Yes Yes   https://www.cardiacdesigns.com  
CardioComm 
Solutions 
HeartCheck 
CardiBeat and ECG 
Pen 
Wireless 
1-lead ECG Yes Yes   https://www.theheartcheck.com  
COALA Wireless 1-lead ECG Yes Yes 
Remote lung 
auscultation https://www.coalalife.com  
Eko DUO Wireless 1-lead ECG Yes Yes  
Remote cardiac 
auscultation/ 
phonocardiogram 
https://www.ekohealth.com  
Omron Blood 
Pressure + EKG 
Monitor 
Wireless 
1-lead 
ECG+BP cuff 
No Yes United States and Canada only  https://omronhealthcare.com  
EKGraph Wireless 1-lead ECG  No Yes United States https://sonohealth.org  
Mobile cardiac 
telemetry 
devices 
Qardio  
QardioCore 
Chest strap 
1-lead ECG Yes No 
ECG, HR, HRV, 
RR, activity 
https://www.getqardio.com/
qardiocore-wearable-ecg-ekg-
monitor-iphone  
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  Device Type CE mark FDA clearance 
Additional 
features/Notes Website 
BardyDx CAM Patch 1-lead ECG Yes Yes 
Under clinical 
investigation for 
QTc monitoring 
in COVID-19 
patients 
https://www.bardydx.com  
BioTel Heart Patch 1-lead ECG 
Yes—only 
for 
extended 
Holter 
Yes FDA cleared for QTc monitoring 
https://www.myheartmonitor
.com/device/mcot-patch  
iRhythm Zio 
patch/Zio AT 
Patch 
1-lead ECG Yes Yes   https://www.irhythmtech.com  
InfoBionic MoMe 
Kardia 
Wired 
3-lead ECG  Yes Yes 
Remote lung 
auscultation https://infobionic.com  
MediBioSense 
MBS HealthStream, 
VitalPatch, MCT  
Patch 
1-lead ECG Yes Yes 
Monitors up to 8 
vital signs https://www.medibiosense.com  
MEMO Patch Patch/watch 1-lead ECG No No 
Asia; Korea FDA 
approved https://www.huinno.com     
Medilynx 
PocketECG 
Wired 
3-lead ECG Yes Yes HRV https://www.pocketecg.com  
RhythMedix 
RhythmStar 
Wired 
3-lead ECG No Yes   https://www.rhythmedix.com  
Samsung S-patch 
Cardio 
Patch 
1-lead ECG Yes No 
Asia; Korea FDA 
approved 
https://www.samsungsds.co
m/global/en/solutions/off/car
dio/cardio.html  
Smartwatches 
Apple Watch 1-lead ECG Yes Yes FDA cleared for AF notification https://www.apple.com/watch  
Withings Move ECG 1-lead ECG Yes No 
Requires Health 
Mate app for ECG 
analysis/AF 
detection 
https://www.withings.com/us
/en/move-ecg  
AF = atrial fibrillation; AZM = azithromycin; BP = blood pressure; ECG = electrocardiogram; FDA = Food & Drug 
Administration; HCQ = hydroxychloroquine; HR = heart rate; HRV = heart rate variability; RR = respiratory rate. 
Additional diagnostic information might be obtained without in-person contact using home enrollment of 
prescribed ambulatory rhythm monitors. Patch monitors can be mailed to patient homes and easily self-
affixed, unlike Holter monitors with cables and electrodes requiring placement by health care workers. In 
some cases, new or follow-up telehealth visits will require an adjunctive in-person visit to perform a 12-
lead ECG, ECG stress test, echocardiogram, or other diagnostic procedures. Occasionally, conventional 
clinic visits are required to accurately assess the impact of comorbidities or frailty on procedural risk, or 
to allow comfortable discussion with multiple family members when planning procedures with high risk. 
Telephone-only visits (ie, without video) may allow for a broader reach due to ease and ubiquitous 
accessibility as a communication strategy for immediate access for urgent matters.  
There are many barriers to implementation, such as inadequate reimbursement, licensing/regulatory and 
privacy issues, lack of infrastructure, resistance to change, lack of access/poor Internet coverage, 
restricted financial resources, and limited technical skills (eg, in the elderly patient population). Some 
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telehealth and remote ECG monitoring technologies may be simply unaffordable and/or unavailable, 
leading to different levels of uptake within communities and across the globe. All stakeholders should 
collaborate to address these challenges and promote the safe and effective use of digital health during 
the current pandemic. In recent months, regulations have been eased to permit consults with new 
patients, issuing prescriptions, and obtaining consents. In that sense, the COVID-19 pandemic may serve 
as an opportunity to evolve current technologies into indispensable tools for our future cardiological 
practice. 
3. Therapy for COVID-19 and potential electrical effects 
No specific cure exists for COVID-19.28-30 Potential COVID-19 therapies, especially hydroxychloroquine and 
azithromycin, are being investigated in ongoing trials but also have been used off label in many parts of 
the world. These may exert QT-prolonging effects31 (Table 3) and, since recent observational data have 
questioned their efficacy, require a careful risk-benefit adjudication.32 Combination therapy (eg, 
hydroxychloroquine and azithromycin) may have synergistic effects on QT prolongation.33,34 In a 
retrospective cohort study of 1,438 COVID-19 patients hospitalized in metropolitan New York (ie, a disease 
epicenter), cardiac arrest was more frequent in patients who received hydroxychloroquine with 
azithromycin compared with patients who received neither drug.35 The adjusted hazard ratio for in-
hospital mortality for treatment with hydroxychloroquine alone was 1.08, for azithromycin alone was 
0.56, and for combined hydroxychloroquine and azithromycin was 1.35. However, none of these hazard 
ratios were statistically significant. The observational design of this study may limit interpretation of these 
findings. In the absence of clear efficacy data, treatment options should be individualized taking into 
account their proarrhythmic potential for torsade de pointes, which may be enhanced by concomitant 
administration of other QT-prolonging drugs (eg, antiarrhythmics, psychotropics, etc). 
Table 3  Effect on QTc and proarrhythmia of experimental pharmacological therapies for COVID-1936  
 QTc prolongation TdP risk 
Chloroquine37-40 Moderate ↑ Low risk of TdP 
Hydroxychloroquine41 Moderate ↑ Low risk of TdP 
Azithromycin42-48 Moderate ↑ Very low risk of TdP 
Lopinavir/ritonavir37 Moderate ↑ Low risk of TdP 
Tocilizumab49 Mild ↑ or ↓ NR 
Fingolimod Mild ↑ NR 
Remdesivir NR NR 
Interferon alfacon-1 NR NR 
Ribavirin NR NR 
Methylprednisolone NR NR 
NR = not reported; TdP = torsade de pointes. 
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In COVID-19 patients receiving prior antiarrhythmic therapy, there should be a thorough consideration of 
risk vs benefit before initiating any QT-prolonging COVID-19 therapies, especially considering their 
unproven value. For instance, although some recent observational studies highlight adverse effects of 
hydroxychloroquine in treating this infectious disease, its use is likely to persist outside of randomized 
trials because of its affordability and global availability compared with, for example, remdesivir.35 If one 
of these drugs is judged to be critical, monitoring should be initiated. If life-threatening arrhythmias 
(VT/VF) occur, the benefit of antiarrhythmic drugs, notably amiodarone, outweighs the potential harm of 
hydroxychloroquine or other QT-prolonging drugs targeting COVID-19, and in these cases antiarrhythmic 
drugs should be prioritized and used as deemed necessary. Most importantly, all modifiable predisposing 
factors for QTc prolongation (electrolyte disturbances, drug-to-drug interaction) that may enhance 
arrhythmia susceptibility should be corrected, and the small subset of individuals with an underlying 
genetic predisposition such as congenital long QT syndrome (in whom QTc-prolonging medications are 
contraindicated) should be identified. Additionally, caution must be exercised in case of subclinical or 
manifest myocarditis that may increase the vulnerability to proarrhythmias associated with QT-prolonging 
drugs.  
If drugs that exert a QT-prolonging effect are to be initiated in an inpatient setting, a baseline 12-lead ECG 
should be acquired. Following review of the QTc, patients can be stratified into low-risk group (QTc of 
<500 ms or <550 ms in the setting of wide baseline QRS) or high-risk group (baseline QTc of ≥500 ms or 
≥550 ms in the setting of wide baseline QRS, or patients who are started on combination therapies), 
guiding selection of telemetered vs nonmonitored beds.50 Low-risk patients treated with QT-prolonging 
agents may be monitored using MCT (or another available wearable) with twice-a-day transmission of 
QTc measurements and any urgent alerts. High-risk patients would require more continuous monitoring 
and follow-up QTc measurements using telemetry preferably (but if unavailable, other remote monitoring 
devices). A second QTc assessment via telemetry or other remote devices after 2 doses may be helpful in 
identifying “QTc reactors”—patients who have an exaggerated response to QT-prolonging agents. An 
increase in QTc by ≥60 ms or to QTc ≥500 ms on any follow-up QT assessment is considered significant 
and should prompt a reassessment of risks vs benefits of continuing the drug.  
In the outpatient setting, a recent statement from the US Food & Drug Administration (FDA) “cautions 
against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical 
trial due to risk of heart rhythm problems.” (This does not affect FDA-approved uses for malaria, lupus, 
and rheumatoid arthritis.)51 Exceptions to this practice are acknowledged to occur in some regions, as 
these drugs have been used outside the United States without regulatory warnings. Under these 
conditions, or when these drugs are maintained after hospital discharge, consumer mobile ECG devices 
capable of generating QTc measurements may be used. If the QTc increases significantly, physicians can 
consider a change or discontinuation of medication via the phone or virtual medical services.  
Electrocardiographic monitoring during clinical trials 
Several double- and multi-arm blind randomized controlled trials are underway worldwide for COVID-19 
outpatients utilizing different medications that may prolong the QT interval.52-56 These drugs are being 
tested either alone or in various combinations and are being compared with one another, with differential 
dosing regimens and/or placebo. These drugs are also being tested for postexposure prophylaxis in high-
risk groups.  
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Mobile health using smartphone-based portable ECG devices as QTc monitoring tools is an innovative and 
economical solution to conduct monitoring in outpatient trials. For instance, in one trial evaluating 
hydroxychloroquine and azithromycin (hydroxychloroquine alone and hydroxychloroquine/azithromycin 
combination) against a placebo, participants receive remote training to acquire a 6-lead ECG at baseline 
and then at specified follow-up intervals through the trial period (Figure 1). These ECGs are transmitted 
to a remote QTc monitoring site, where the QTc is assessed and monitored over the treatment period.  
 
 
Figure 1     Electrocardiogram (ECG) acquisition and transmission using a smartphone-based portable ECG monitor. 
 
4. The future: Digital medicine catalyzed by the pandemic  
The COVID-19 public health emergency has forced changes to traditional norms of health care access and 
delivery across all continents.10 It has accelerated adoption of telemedicine and all aspects of digital 
health, regarded as a positive development. Today’s new reality will likely define medicine going forward. 
Many monitoring and diagnostic testing aspects of both inpatient and outpatient care will be increasingly 
served by digital medicine tools. 
The need for contactless monitoring for inpatients triaged to intensive care unit, telemetry, or 
nonconventional environments, as well as for outpatients needing continued management, has triggered 
novel implementation of digital health monitoring tools. Some centers have created algorithms based on 
predictive analytics of electronic medical record (EMR) data. Centralized monitoring or mobile continuous 
monitoring has improved patient outcomes, reduced manpower needs, and is being utilized more 
commonly.57 The use of wearables such as watches, smartphones, and smart beds (with elimination of 
cables and skin electrodes) for in-hospital telemetry is a novel approach. This type of wireless monitoring 
may be continued after discharge, permitting prolonged surveillance of rhythm and other physiological 
parameters.12 Bracelet technologies may transmit multiple parameters (eg, heart rate, sleep, oxygen 
desaturation index, blood pressure) via a smartphone link to centralized hubs. These technologies provide 
a solution for intensive monitoring extending beyond the hospital environment.  
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Outpatient management has been revolutionized since the start of the pandemic. Social distancing 
measures and restricted clinic access have driven the rapid adoption of telehealth mechanisms to 
continue management of non-COVID-19 patients. Virtual visits that have been used for decades to reach 
isolated communities,58 but less commonly utilized in advanced health systems, have now become the 
mainstay of ambulatory care across all subspecialties. The initial experience appears to have been positive 
for both patient and caregiver. Heart rhythm professionals are fortunate to have a choice of wireless 
technologies to relay monitored information to maintain connection.12 Wearable and smartphone-based 
devices allow convenient real-time monitoring for arrhythmias on a long-term basis due to the comfort 
associated with their small size and ease of use while reducing patient and health care worker exposure. 
Remote CIED monitoring has existed for decades.24 It is strongly endorsed by professional societies, but 
in practice only a fraction of its diagnostic and therapeutic capabilities has been utilized—until now.59 
Since the start of the pandemic, utilization of wireless communication with CIEDs has grown exponentially, 
permanently altering the future of device follow-up. Patient outcomes may be improved with intensive 
device-based monitoring compared with traditional in-clinic evaluations at regular intervals.60 Recent data 
indicate that in-person CIED evaluation can be extended safely to at least biennially when daily digital 
connectivity is maintained.61 Remote monitoring has the potential advantage of detecting and alerting 
caregivers (and in the future—patients directly) about important parameter changes, enabling earlier 
patient hospitalization, even during a presymptomatic phase.62 
Connectivity permits longitudinal follow-up, with advantages ranging from individual disease 
management to assessment of penetration of recommended therapies into communities.60,63 The ability 
for CIED remote monitoring data to be streamed to or accessed by multiple providers can facilitate 
communication and cooperative treatment and should be encouraged. This will require approval by 
patients, regulators, and manufacturers. Lessons learned from implantable devices can be applied widely 
in telemedicine. Regulatory bodies have been responsive, for example, approving smartphone-based QT 
interval measurement and telehealth services across state lines in the United States. The pandemic 
experience should serve as an impetus to expedite the resolution of persistent challenges, such as 
validation of digital technologies, infrastructure for data management (and mechanism for relay to patient 
and caregiver), interoperability with EMR, application of predictive analytics, cybersecurity (and with it 
the capability for limited forms of remote CIED programming), and reimbursement.64-66  
In summary, the crisis precipitated by the pandemic has catalyzed the adoption of remote patient 
management across many specialties and for heart rhythm professionals, in particular. This practice is 
here to stay—it will persist even if other less arrhythmogenic treatment strategies evolve for COVID-19 
and after the pandemic has passed. This is an opportunity to embed and grow remote services in everyday 
medical practice worldwide. 
References 
1. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 
[published online April 17, 2020]. doi: 101056/NEJMc2010419. 
2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel 
coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–1069. 
11 
 
3. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with 
coronavirus disease 2019 (COVID-19). JAMA Cardiol [published online March 27, 2020]. doi: 
10.1001/jamacardio.2020.1017. 
4. Azarkish M, Laleh Far V, Eslami M, Mollazadeh R. Transient complete heart block in a patient with 
critical COVID-19. Eur Heart J [published online April 14, 2020]. doi: 10.1093/eurheartj/ehaa307. 
5. Noll A, William A, Varma N. A young woman presenting with a viral prodrome, palpitations, 
dizziness, and heart block. JAMA Cardiol 2020 [In press]. 
6. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in 
patients with COVID-19. J Cardiovasc Electrophysiol 2020;31:1003–1008. 
7. Yao XH, Li TY, He ZC, et al. [A pathological report of three COVID-19 cases by minimal invasive 
autopsies]. Zhonghua Bing Li Xue Za Zhi 2020;49:411–417. 
8. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 
2019 (COVID-19). JAMA Cardiol [published online March 27, 2020]. doi: 
10.1001/jamacardio.2020.1096. 
9. Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on minimizing risk of drug-induced ventricular 
arrhythmia during treatment of COVID-19: a statement from the Canadian Heart Rhythm Society. 
Can J Cardiol [published online April 8, 2020]. doi: 10.1016/j.cjca.2020.04.003. 
10. Udwadia ZF, Raju RS. How to protect the protectors: 10 lessons to learn for doctors fighting the 
COVID-19 coronavirus. Med J Armed Forces India 2020;76:128–131. 
11. Gabriels J, Saleh M, Chang D, Epstein LM. Inpatient use of mobile continuous telemetry for COVID-
19 patients treated with hydroxychloroquine and azithromycin. HeartRhythm Case Rep 
2020;6:241–243. 
12. Steinberg JS, Varma N, Cygankiewicz I, et al. 2017 ISHNE-HRS expert consensus statement on 
ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm 2017;14:e55–e96. 
13. Garabelli P, Stavrakis S, Albert M, et al. Comparison of QT interval readings in normal sinus rhythm 
between a smartphone heart monitor and a 12-lead ECG for healthy volunteers and inpatients 
receiving sotalol or dofetilide. J Cardiovasc Electrophysiol 2016;27:827–832. 
14. Castelletti S, Dagradi F, Goulene K, et al. A wearable remote monitoring system for the 
identification of subjects with a prolonged QT interval or at risk for drug-induced long QT 
syndrome. Int J Cardiol 2018;266:89–94. 
15. Gropler MRF, Dalal AS, Van Hare GF, Silva JNA. Can smartphone wireless ECGs be used to 
accurately assess ECG intervals in pediatrics? A comparison of mobile health monitoring to 
standard 12-lead ECG. PLoS One 2018;13:e0204403. 
16. US Food & Drug Administration. VitalConnect, Inc. VitalPatch: Letter of Authorization [April 26, 
2020]. Available from https://www.fda.gov/media/137397/download. Accessed May 15, 2020. 
17. VitalConnect. COVID-19.  Available from https://vitalconnect.com/covid-19-remote-patient-
monitoring. Accessed May 15, 2020. 
18. Rimmer LK, Rimmer JD. Comparison of 2 methods of measuring the QT interval. Am J Crit Care 
1998;7:346–354. 
19. Rimmer LK. Bedside monitoring of the QT interval. Am J Crit Care 1998;7:183–189. 
12 
 
20. Koltowski L, Balsam P, Glłowczynska R, et al. Kardia Mobile applicability in clinical practice: a 
comparison of Kardia Mobile and standard 12-lead electrocardiogram records in 100 consecutive 
patients of a tertiary cardiovascular care center. Cardiol J [published online January 15, 2019]. doi: 
10.5603/CJ.a2019.0001. 
21. Ohannessian R. Telemedicine: potential applications in epidemic situations. European Research in 
Telemedicine 2015;4:95–98. 
22. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med 2020;382:1679–
1681. 
23. Liu S, Yang L, Zhang C, et al. Online mental health services in China during the COVID-19 outbreak. 
Lancet Psychiatry 2020;7:e17–e18. 
24. Varma N, Ricci RP. Telemedicine and cardiac implants: what is the benefit? Eur Heart J 
2013;34:1885–1895. 
25. NHSX. Information governance. Available from https://www.nhsx.nhs.uk/covid-19-response/data-
and-information-governance/information-governance. Accessed May 15, 2020. 
26. NHS Digital. Approved video consultation systems. Available from 
https://digital.nhs.uk/services/future-gp-it-systems-and-services/approved-econsultation-systems. 
Accessed May 15, 2020. 
27. National Health Service. Procurement of pre-approved suppliers of online and video consultation 
systems for GP practices to support COVID-19. Available from 
https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/C0079-Suppliers-
of-online-and-video-consultations.pdf. Accessed April 29, 2020. 
28. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-
19. N Engl J Med [published online April 10, 2020]. doi: 10.1056/NEJMoa2007016. 
29. European Society of Cardiology. ESC guidance for the diagnosis and management of CV disease 
during the COVID-19 pandemic. Available from https://www.escardio.org/Education/COVID-19-
and-Cardiology/ESC-COVID-19-Guidance. Accessed April 29, 2020. 
30. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a 
randomized clinical trial. medRxiv 2020.2003.2022.20040758. 
31. Haeusler IL, Chan XHS, Guérin PJ, White NJ. The arrhythmogenic cardiotoxicity of the quinoline and 
structurally related antimalarial drugs: a systematic review. BMC Med 2018;16:200. 
32. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients 
with Covid-19. N Engl J Med [published online May 7, 2020]. doi: 10.1056/NEJMoa2012410. 
33. Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients 
with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm [published online 
May 11, 2020]. doi: 10.1016/j.hrthm.2020.05.014. 
34. Saleh M, Gabriels J, Chang D, et al. The effect of chloroquine, hydroxychloroquine and azithromycin 
on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythm Electrophysiol 
[published online April 29, 2020]. doi: 10.1161/CIRCEP.120.008662. 
35. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or 
azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 
[published online May 11, 2020]. doi: 10.1001/jama.2020.8630. 
13 
 
36. CredibleMeds. COVID-19 experimental therapies and TdP risk. Available from 
https://www.crediblemeds.org/blog/covid-19-experimental-therapies-and-tdp-risk. Accessed April 
20, 2020. 
37. Vicente J, Zusterzeel R, Johannesen L, et al. Assessment of multi-ion channel block in a phase I 
randomized study design: results of the CiPA phase I ECG biomarker validation study. Clin 
Pharmacol Ther 2019;105:943–953. 
38. Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate 
antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007;2:e6. 
39. Wozniacka A, Cygankiewicz I, Chudzik M, Sysa-Jedrzejowska A, Wranicz JK. The cardiac safety of 
chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on 
arrhythmia, heart rate variability and repolarization parameters. Lupus 2006;15:521–525. 
40. Teixeira RA, Martinelli Filho M, Benvenuti LA, Costa R, Pedrosa AA, Nishióka SA. Cardiac damage 
from chronic use of chloroquine: a case report and review of the literature. Arq Bras Cardiol 
2002;79:85–88. 
41. McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G, Touma Z. Electrocardiogram abnormalities 
related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol 2018;36:545–551. 
42. Zhang M, Xie M, Li S, et al. Electrophysiologic studies on the risks and potential mechanism 
underlying the proarrhythmic nature of azithromycin. Cardiovasc Toxicol 2017;17:434–440. 
43. Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk evaluation of azithromycin-induced QT prolongation 
in real-world practice. Biomed Res Int 2018;2018:1574806. 
44. US Food and Drug Administration. ZITHROMAX (azithromycin) for IV infusion only. Highlights of 
prescribing information. Reference ID: 4051690. Available from 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050733s043lbl.pdf. Accessed May 
20, 2020. 
45. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular 
death. N Engl J Med 2012;366:1881–1890. 
46. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de 
pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug 
Saf 2010;33:303–314. 
47. Cheng YJ, Nie XY, Chen XM, et al. The role of macrolide antibiotics in increasing cardiovascular risk. 
J Am Coll Cardiol 2015;66:2173–2184. 
48. Maisch NM, Kochupurackal JG, Sin J. Azithromycin and the risk of cardiovascular complications. J 
Pharm Pract 2014;27:496–500. 
49. Grange S, Schmitt C, Banken L, Kuhn B, Zhang X. Thorough QT/QTc study of tocilizumab after single-
dose administration at therapeutic and supratherapeutic doses in healthy subjects. Int J Clin 
Pharmacol Ther 2011;49:648–655. 
50. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and 
circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for 
coronavirus disease 19 (COVID-19). Mayo Clin Proc 2020;95:1213–1221. 
51. US Food & Drug Administration. FDA cautions against use of hydroxychloroquine or chloroquine for 
COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems.  
14 
 
Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-
hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or. Accessed April 29, 2020. 
52. ClinicalTrials.gov. COVID-19 clinical trials. Available from 
https://clinicaltrials.gov/ct2/results?cond=COVID+19&term=&cntry=&state=&city=&dist=. 
Accessed April 18, 2020. 
53. ClinicalTrials.gov. Efficacy of novel agents for treatment of SARS-CoV-2 infection among high-risk 
outpatient adults: an adaptive randomized platform trial. Available from 
https://clinicaltrials.gov/ct2/show/NCT04354428?type=Intr&cond=COVID+19&map_cntry=US&ma
p_state=US%3AWA&draw=2. Accessed April 26, 2020. 
54. ClinicalTrials.gov. WU 352: open-label, randomized controlled trial of hydroxychloroquine alone or 
hydroxychloroquine plus azithromycin or chloroquine alone or chloroquine plus azithromycin in the 
treatment of SARS CoV-2 infection. Available from 
https://clinicaltrials.gov/ct2/show/NCT04341727?type=Intr&cond=COVID+19&map_cntry=US&ma
p_state=US%3AMO&draw=2. Accessed April 26, 2020. 
55. ClinicalTrials.gov. Efficacy of hydroxychloroquine for post-exposure prophylaxis (PEP) to prevent 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to 
coronavirus disease (COVID-19): a blinded, randomized study. Available from 
https://clinicaltrials.gov/ct2/show/NCT04328961?type=Intr&cond=COVID+19&map_cntry=US&ma
p_state=US%3AWA&draw=2. Accessed April 26, 2020. 
56. ClinicalTrials.gov. ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial).  
Available from 
https://clinicaltrials.gov/ct2/show/NCT04352933?type=Intr&cond=COVID+19&draw=2. Accessed 
April 26, 2020. 
57. Cantillon DJ, Loy M, Burkle A, et al. Association between off-site central monitoring using 
standardized cardiac telemetry and clinical outcomes among non-critically ill patients. JAMA 
2016;316:519–524. 
58. Bagchi S. Telemedicine in rural India. PLoS Med 2006;3:e82. 
59. Slotwiner D, Varma N, Akar JG, et al. HRS expert consensus statement on remote interrogation and 
monitoring for cardiovascular implantable electronic devices. Heart Rhythm 2015;12:e69–e100. 
60. Hindricks G, Varma N, Kacet S, et al. Daily remote monitoring of implantable cardioverter 
defibrillators: insights from the pooled patient-level data from three randomised controlled trials 
(IN-TIME, ECOST, TRUST). Eur Heart J 2017;38:1749–1755. 
61. Watanabe E, Yamazaki F, Goto T, et al. Remote management of pacemaker patients with biennial 
in-clinic evaluation: continuous home monitoring in the Japanese at-home study: a randomized 
clinical trial. Circ Arrhythm Electrophysiol 2020;13:e007734. 
62. Varma N, Pavri BB, Stambler B, Michalski J. Same-day discovery of implantable cardioverter 
defibrillator dysfunction in the TRUST remote monitoring trial: influence of contrasting messaging 
systems. Europace 2013;15:697–703. 
63. Varma N, Jones P, Wold N, Stein K. How well do results from large randomized clinical trials diffuse 
into clinical practice? Impact of MADIT-RIT in a large cohort of implantable cardioverter 
defibrillator patients (ALTITUDE). Eur Heart J 2014;35(Suppl. 1) [Abstract]. 
15 
 
64. Saxon LA, Varma N, Epstein LM, Ganz LI, Epstein AE. Factors influencing the decision to proceed to 
firmware upgrades to implanted pacemakers for cybersecurity risk mitigation. Circulation 
2018;138:1274–1276. 
65. Slotwiner DJ, Abraham RL, Al-Khatib SM, et al. HRS white paper on interoperability of data from 
cardiac implantable electronic devices (CIEDs). Heart Rhythm 2019;16:e107–e127. 
66. Heidbuchel H, Hindricks G, Broadhurst P, et al. EuroEco (European Health Economic Trial on Home 
Monitoring in ICD Patients): a provider perspective in five European countries on costs and net 
financial impact of follow-up with or without remote monitoring. Eur Heart J 2015;36:158–169. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
Appendix 1     Author disclosure table 
Writing group 
member Employment 
Honoraria/ 
Speaking/ 
Consulting 
Speakers’ 
bureau Research* 
Fellowship 
support* 
Ownership/ 
Partnership/
Principal/ 
Majority 
stockholder 
Stock 
or 
stock 
options 
Intellectual 
property/ 
Royalties 
Other 
Niraj Varma, MA, 
MD, PhD, FACC, 
FRCP (Chair) 
Cleveland Clinic, Cleveland, 
Ohio 
1: BIOTRONIK; 1: 
EP Solutions; 1: 
Medtronic; 1: 
MicroPort 
None 1: Boston 
Scientific; 2: 
Abbott 
None None None None None 
Nassir F. 
Marrouche, MD, 
FHRS (Vice-
Chair) 
Tulane University School of 
Medicine, New Orleans, 
Louisiana 
0: Biosense 
Webster; 0: 
BIOTRONIK; 0: 
Cardiac Design; 
0: Medtronic; 1: 
Preventice 
None 0: Abbott; 0: 
Boston 
Scientific; 0: GE 
Healthcare; 5: 
Biosense 
Webster 
None None None None None 
Luis Aguinaga, 
MD, MBA, PhD, 
FESC, FACC 
Centro Privado de 
Cardiología, Tucuman, 
Argentina 
None None None None None None None None 
Christine M. 
Albert, MD, 
MPH, FHRS, 
FACC 
Cedars-Sinai Medical Center, 
Los Angeles, California 
1: Roche 
Diagnostics 
None 5: Abbott; 5: 
NIH; 5: Roche 
Diagnostics 
None None None None None 
Elena Arbelo, 
MD, MSci, PhD  
Arrhythmia Section, 
Cardiology Department, 
Hospital Clínic, Universitat de 
Barcelona, Barcelona, Spain; 
Institut d’Investigacións 
Biomèdiques August Pi i 
Sunyer (IDIBAPS), Barcelona, 
Spain; Centro de 
Investigación Biomédica en 
Red de Enfermedades 
Cardiovasculares (CIBERCV), 
Madrid, Spain 
1: Biosense 
Webster 
None None None None None None None 
Jong-Il Choi, MD, 
PhD, MHS 
Korea University Medical 
Center, Seoul, Republic of 
Korea 
None None None None None None None None 
Mina K. Chung, 
MD, FHRS, FACC 
Cleveland Clinic, Cleveland, 
Ohio 
2: ABIM None 5: AHA; 5: NIH None None None 1: Elsevier; 1: 
UpToDate 
0: ACC (EP Section Leadership 
Council member); 0: AHA (Chair, 
ECG & Arrhythmias Committee; 
Member, Clinical Cardiology 
Leadership Committee; Member, 
17 
 
Writing group 
member Employment 
Honoraria/ 
Speaking/ 
Consulting 
Speakers’ 
bureau Research* 
Fellowship 
support* 
Ownership/ 
Partnership/
Principal/ 
Majority 
stockholder 
Stock 
or 
stock 
options 
Intellectual 
property/ 
Royalties 
Other 
Committee on Scientific Sessions 
Programming); 0: Amarin (Data 
monitoring committee member); 
0: BIOTRONIK (EPIC Alliance 
steering committee member); 2: 
AHA (Associate Editor, Circulation: 
Arrhythmia and Electrophysiology) 
Giulio Conte, 
MD, PhD 
Cardiocentro, Lugano, 
Switzerland 
None None 5: Boston 
Scientific; 5: 
Swiss National 
Science 
Foundation  
None None None None None 
Lilas Dagher, MD Tulane University School of 
Medicine, New Orleans, 
Louisiana 
None None None None None None None None 
Laurence M. 
Epstein, MD, 
FACC  
Northwell Health, North 
Shore University Hospital, 
Manhasset, New York 
1: Abbott; 2: 
Medtronic; 2: 
Spectranetics 
Corporation 
None None None None None None 2: Boston Scientific (Clinical Events 
Committee) 
Hamid Ghanbari, 
MD, FACC 
University of Michigan, Ann 
Arbor, Michigan 
2: Preventice None 1: BIOTRONIK; 
1: Boston 
Scientific; 1: 
Medtronic; 1: 
Toyota 
None None None None 1: Preventice 
(Travel/Entertainment) 
Janet K. Han, 
MD, FHRS, FACC 
VA Greater Los Angeles 
Healthcare System and David 
Geffen School of Medicine at 
the University of California, 
Los Angeles, Los Angeles, 
California 
1: Abbott; 1: 
Medtronic 
None None None None None None None 
Hein Heidbuchel, 
MD, PhD, FESC, 
FEHRA 
Antwerp University and 
University Hospital, Antwerp, 
Belgium 
None None None None None None None None 
He Huang, MD, 
FACC, FESC, 
FEHRA 
Renmin Hospital of Wuhan 
University, Wuhan, China 
None None None None None None None None 
18 
 
Writing group 
member Employment 
Honoraria/ 
Speaking/ 
Consulting 
Speakers’ 
bureau Research* 
Fellowship 
support* 
Ownership/ 
Partnership/
Principal/ 
Majority 
stockholder 
Stock 
or 
stock 
options 
Intellectual 
property/ 
Royalties 
Other 
Dhanunjaya R. 
Lakkireddy, MD, 
FHRS, FACC  
Kansas City Heart Rhythm 
Institute and Research 
Foundation, Overland Park, 
Kansas 
1: BIOTRONIK; 2: 
Abbott  
1: Abiomed; 
1: Biosense 
Webster; 1: 
Boston 
Scientific; 2: 
Janssen  
None None None None None None 
Tachapong 
Ngarmukos, MD, 
FAPHRS, FACC  
Faculty of Medicine 
Ramathibodi Hospital, 
Mahidol University, Bangkok, 
Thailand 
1: Abbott; 1: 
Bayer; 1: 
Biosense  
Webster; 1: 
BIOTRONIK; 1: 
Boehringer 
Ingelheim; 1: 
Boston Scientific; 
1: Daiichi 
Sankyo; 1: 
Medtronic; 1: 
Pfizer 
None None None None None None None 
Andrea M. 
Russo, MD, 
FHRS, FACC 
Cooper Medical School of 
Rowan University, Camden, 
New Jersey 
None None 1: MediLynx; 2: 
Boehringer 
Ingelheim; 2: 
Boston 
Scientific 
None None None 1: UpToDate 0: ABIM (Member, ABIM 
Cardiovascular Board); 0: Apple 
Inc. (Steering Committee Apple 
Heart Study); 0: Boston Scientific 
(Steering Committee, Research) 
Eduardo B. Saad, 
MD, PhD, FHRS, 
FESC 
Hospital Pró-Cardíaco, Rio de 
Janeiro, Brazil 
1: Biosense 
Webster 
None None None None None None 1: Abbott (Travel/Entertainment) 
Luis C. Saenz 
Morales, MD 
CardioInfantil Foundation, 
Cardiac Institute, Bogota, 
Colombia 
None None None None None None None None 
Kristin E. Sandau, 
PhD, RN 
Bethel University, St. Paul, 
Minnesota 
1: Japanese 
Association of 
Cardiovascular 
Nursing  
None None None None None None 1: Patient Safety Authority  
Arun Raghav M. 
Sridhar, MD, 
MPH, FACC 
University of Washington, 
Seattle, Washington 
 None None None None None None None None 
19 
 
Writing group 
member Employment 
Honoraria/ 
Speaking/ 
Consulting 
Speakers’ 
bureau Research* 
Fellowship 
support* 
Ownership/ 
Partnership/
Principal/ 
Majority 
stockholder 
Stock 
or 
stock 
options 
Intellectual 
property/ 
Royalties 
Other 
Eric C. Stecker, 
MD, MPH, FACC  
Oregon Health & Science 
University, Portland, Oregon 
None  None 4: AHA None None None None None 
Paul D. Varosy, 
MD, FHRS, FACC 
VA Eastern Colorado Health 
Care System and University 
of Colorado, Aurora, 
Colorado 
None None  4: NIH None None None None 0: ACC (Committee Chair); 0: AHA 
(Committee Member); 0: NCDR 
(Committee Chair/Member) 
Number value: 0 = $0; 1 = ≤ $10,000; 2 = > $10,000 to ≤ $25,000; 3 = > $25,000 to ≤ $50,000; 4 = > $50,000 to ≤ $100,000; 5 = > $100,000.  
*Research and fellowship support are classed as programmatic support. Sources of programmatic support are disclosed but are not regarded as a relevant relationship with 
industry for writing group members or reviewers. ABIM = American Board of Internal Medicine; ACC = American College of Cardiology; AHA = American Heart Association; NCDR 
= National Cardiovascular Data Registry; NIH = National Institutes of Health. 
